Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) have earned a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.50.
A number of analysts recently weighed in on CATX shares. Piper Sandler lowered their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Bank of America cut their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. BMO Capital Markets set a $11.00 price objective on Perspective Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, BTIG Research reissued a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th.
Read Our Latest Stock Report on Perspective Therapeutics
Perspective Therapeutics Trading Down 3.3%
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. On average, sell-side analysts anticipate that Perspective Therapeutics will post -1.03 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of CATX. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $28,000. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $31,000. AXQ Capital LP lifted its holdings in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics during the 4th quarter valued at about $35,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
- Five stocks we like better than Perspective Therapeutics
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
